PharmaShots | Incisive News in 3 Shots

Subscribe Now

Novaliq

Novaliq Reports the EMA Acceptance of MAA for CyclASol (ciclosporin ophthalmic solution) to Treat Dry Eye Disease

Novaliq Reports the EMA Acceptance of MAA for CyclASol (ciclosporin ophthalmic solution) to Treat Dry Eye Disease

August 24, 2023

PharmaShots' Key Highlights of Second Quarter 2022

PharmaShots' Key Highlights of Second Quarter 2022

June 30, 2022

Novaliq Presents Results of Cyclasol in P-III (ESSENCE-2) Trial for the Treatment of Dry Eye Disease at ASCRS 2022

Novaliq Presents Results of Cyclasol in P-III (ESSENCE-2) Trial for the Treatment of Dry Eye Disease at ASCRS 2022

April 27, 2022

Novaliq Reports Results of CyclASol in P-III (ESSENCE-2) Trial for the Treatment of Dry Eye Disease

Novaliq Reports Results of CyclASol in P-III (ESSENCE-2) Trial for the Treatment of Dry Eye Disease

December 22, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us